Peginterferon alfa-2b and ribaviran for 12 vs. 24 weeks in HCV genotype 2 or 3

Article Abstract:

A randomized trial in patients with HCV genotype 2 or 3 comparing the standard 24-week regimen with a variable-duration regime is conducted. The findings indicate that a shorter course of therapy over 12 weeks with peginterferon alfa-2b and ribavirin is as effective as a 24-week course for patients with HCV genotype 2 or 3 who have a response to treatment at 4 weeks.

Drug therapy, Dosage and administration, Hepatitis C virus, Ribavirin (Medication)

---

Gamma-Hydroxybutyric acids

Article Abstract:

The Gamma-Hydroxybutyric Acid (GHB) was synthesized in 1960 in an attempt to create an analogue of the ubiquitous inhibitory brain neurotransmitter gamma-aminobutyric acid (GABA) that would cross the blood-brain barrier. The findings indicate that GHB is expected to have sedative properties similar to those that were reported for beta-butyrolactone in 1992.

Properties, GABA, Blood-brain barrier, Gamma-hydroxybutyrate, Gamma hydroxybutyrate

---

Similar abstracts:

• Abstracts: MGMT gene silencing and benefit from temozolomide in glioblastoma. Blood lead concentration and delayed puberty in girls
• Abstracts: Levonorgestrel. Ringing the changes in primary care
• Abstracts: Subarachnoid hemorrhage. A guide to using complementary alternative medicines in cancer
• Abstracts: The neurological illness of Eugene O'Neill -- a clinicopathological report. Memory dysfunction
• Abstracts: Family traveler: What's fun for kids in Atlanta. What's fun for kids in Dallas. Family traveler: What's fun for kids in San Antonio

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.